Top Industry Leaders in the Moyamoya Disease Market
Latest Moyamoya Disease Companies Update
Merck & Co. Received US FDA priority review for sotatercept, an experimental therapy for Moyamoya disease and other progressive blood vessel disorders.Target action date for the review is March 26, 2024. Approval would solidify Merck's position in the Moyamoya disease market.
Valenta Pharmaceuticals Launched Ethoxidol, a new generation antioxidant for treating chronic brain ischemia (cerebrovascular insufficiency) associated with Moyamoya disease.Ethoxidol's unique mechanism of action has the potential to improve outcomes for patients with Moyamoya disease.
Abbott Laboratories Continues to market its Xience V balloon expandable stent system for revascularization procedures in Moyamoya disease.Xience V stents are designed to minimize re-narrowing of the artery after angioplasty, a common complication in Moyamoya disease patients.
Boston Scientific Corporation Offers its Solitaire™ FR reperfusion device for minimally invasive treatment of Moyamoya disease-related ischemic strokes.The Solitaire device is effective in removing blood clots and restoring blood flow to the brain.
List of Moyamoya Disease Key Companies in the Market
- Abbott Laboratories
- Boston Scientific Corporation
- Cephalon Inc.
- Cordis Corporation
- Eisai Co. Ltd
- GE Healthcare
- Genentech Inc.
- GlaxoSmithKline PLC.
- Johnson & Johnson
- Koninklijke Philips N.V.
- Medtronic plc
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Siemens
- Stryker
- Sunovion Pharmaceuticals Inc.
- UCB Pharma Ltd.
- Valeant Pharmaceuticals International Inc